InnoCare Pharma Doses First Patient in ICP-488 Study for Autoimmune Diseases
China-based InnoCare Pharma (HKG: 9969) announced that the first subject has been dosed in a...
Clinical trial approval / initiation
Eccogene Receives FDA Approval for ECC4703 Phase I Study in NASH and Dyslipidemia
Shanghai-based biopharmaceutical company Eccogene announced it has received approval from the U.S. Food and Drug...
Lion TCR Enrolls First Patient in LioCyx-M004 Study for HBV-Related Liver Cancer
Singapore-based clinical-stage biotech Lion TCR announced the enrollment of the first subject in a clinical...
Innovent and Laekna Dose First Patient in Afuresertib and Tyvyt Study for PD-1 Resistant Tumors
China’s Innovent Biologics Inc. (HKG: 1801) and partner Laekna Therapeutics Shanghai Co., Ltd announced that...
Mabwell Bioscience Gets FDA Approval for Nectin-4 ADC 9MW2821 in Solid Tumors
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced it has received approval from the...
LaNova Medicines Gets FDA Green Light for LM-305 Myeloma Study
Shanghai-based cancer therapy developer LaNova Medicines Ltd announced it has received approval from the U.S....
MabPharm’s CMAB015 Biosimilar Receives NMPA Approval for Clinical Study
Taizhou-based monoclonal antibody (mAb) biosimilars specialist MabPharm Ltd (HKG: 2181) announced that it has received...
Nuance Pharma Initiates Phase I Study for Ketorolac IV Infusion (NTM-001)
China-based Nuance Pharma announced the initiation of subject enrollment and the first drug infusion in...
SinoPharm CNBG’s F61 Monoclonal Antibody Receives NMPA Clinical Trial Approval
SinoPharm CNBG Wuhan Institute of Biological Products Co., Ltd’s F61, a recombinant broad-spectrum novel coronavirus...
Betta Pharmaceuticals Enrolls First Patient in BPI-442096 Phase I Study for Solid Tumors
China-based Betta Pharmaceuticals (SHE: 300558) announced that the first subject has been enrolled in a...
Hengrui Medicine’s SHR-A1811 Combo Receives NMPA Approval for HER2+ NSCLC Study
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received approval from...
Sirnaomics’ STP705 Receives Approval for Liver Cancer Trial in Taiwan
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced that it has received approval from...
Ascentage Pharma’s Olverembatinib Receives Health Canada Approval for Phase Ib Study
Suzhou-based Ascentage Pharma (HKG: 6855) announced that it has received approval from Health Canada to...
Ji Xing Pharmaceuticals Enrolls First Patient in OC-01 Phase III Study for Dry Eye
Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, announced that the first patient has been...
Gan & Lee Pharmaceuticals Doses First Patient in GZR18 Phase II Study for Diabetes and Obesity
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed...
CANbridge Pharmaceuticals Doses First Patient in CAN103 Gaucher Disease Trial
China-based rare disease firm CANbridge Pharmaceuticals announced the dosing of the first patient in a...
DAC Biotech’s DXC005 ADC Doses First Patient in Beijing Cancer Hospital Trial
China-based Hangzhou DAC Biotech Co., Ltd announced the first patient enrollment and dosing of its...
MicroPort CardioFlow Completes First Clinical Use of Dry Valve Transcatheter Mitral Valve System
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...
Kexing Pharmaceutical Launches Phase III Influenza Vaccine Study in Chile
China-based Kexing Pharmaceutical (SHA: 688136) announced the start of a Phase III clinical trial in...
Henlius Biotech’s HLX14 Biosimilar Wins TGA Approval for Global Phase III Osteoporosis Study
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) received approval from Australia’s Therapeutic Goods Administration (TGA)...